Ownership of Sponsor Drug and Comparator Drug Sample Clauses

Ownership of Sponsor Drug and Comparator Drug. Vlastnictví léku zadavatele a srovnávacího léku. Sponsor Drug and Comparator Drug are and shall remain at all times the property of Sponsor. Sponsor grants Health Service Provider no express or implied intellectual property rights in the Sponsor Drug or and Comparator Drug, or in any methods of making or using the Sponsor Drug or Comparator Drug. Lék zadavatele a srovnávací lék jsou a trvale zůstanou ve vlastnictví zadavatele. Zadavatel neuděluje poskytovateli zdravotních služeb žádná výslovná ani implicitní práva k léku zadavatele a/nebo srovnávacího léku ani jakýmkoli způsobům jejich výroby nebo používání.
AutoNDA by SimpleDocs
Ownership of Sponsor Drug and Comparator Drug. V lastnictví léku zadavatele a srovnávacího léku. Sponsor Drug and Comparator Drug are and shall remain at all times the property of Sponsor. Sponsor grants Institution no express or implied intellectual property rights in the Sponsor Drug or and Comparator Drug, or in any methods of making or using the Sponsor Drug or Comparator Drug. Lék zadavatele a srovnávací lék jsou a trvale zůstanou ve vlastnictví zadavatele. Zadavatel neuděluje zdravotnickému zařízení žádná výslovná ani implicitní práva k léku zadavatele a/nebo srovnávacího léku ani jakýmkoli způsobům jejich výroby nebo používání. The Sponsor at their own expense will arrange for the disposal of the unused medications Likvidaci nevyužitých léků zadavatel zajistí na vlastní náklady. Sponsor undertakes that, as a waste producer, it will at its own expense ensure that unused Study Drug is handed to the authorized person according to Act No. 185/2001 Coll., on Waste, as amended. Zadavatel se jako původce odpadu zavazuje, že zajistí na vlastní náklady, jak v průběhu, tak i po skončení klinického hodnocení, předání nepoužitelného a nepoužitého léčivého přípravku oprávněné osobě v souladu s ustanoveními zákona č. 185/2001 Sb., o odpadech a jeho prováděcími předpisy v platném znění. Sponsor represents to meet any and all conditions stipulated by the relevant legislation concerning the manufacture (import) of the Sponsor Drug and their distribution to the Institution. Zadavatel prohlašuje, že jsou splněny veškeré podmínky stanovené příslušnými právními předpisy pro výrobu (dovoz) léku zadavatele a jeho distribuci do zdravotnického zařízení. The Parties acknowledge and confirm that the Trial, which is subject to this Agreement, is entirely independent from any persuasion to purchase medicinal products (medical devices) from CRO or the Sponsor, or from any decisions to purchase medicinal products (medical devices’) from CRO or the Sponsor, and shall Smluvní strany shodně prohlašují, že klinické hodnocení dle této smlouvy nijak nesouvisí s odběrem léčivých přípravků (zdravotnických prostředků) od CRO nebo zadavatele, jakož i případným rozhodováním o pořízení léčivých prostředků (zdravotnických prostředků) od CRO nebo zadavatele, ani neovlivní existující nebo have no impact on any ongoing or future agreements that may exist between CRO, the Sponsor, and the Institution. budoucí smluvní vztahy mezi CRO, zadavatelem a zdravotnickým zařízením.
Ownership of Sponsor Drug and Comparator Drug. Vlastnictví léku zadavatele a srovnávacího léku. Sponsor Drug and Comparator Drug are and shall remain at all times the property of Sponsor. Sponsor grants Institution no express or implied intellectual property rights in the Sponsor Drug or and Comparator Drug, or in any methods of making or using the Sponsor Drug or Comparator Drug. Lék zadavatele a srovnávací lék jsou a trvale zůstanou ve vlastnictví zadavatele. Zadavatel neuděluje zdravotnickému zařízení žádná výslovná ani implicitní práva k léku zadavatele a/nebo srovnávacího léku ani jakýmkoli způsobům jejich výroby nebo používání. The Sponsor at their own expense will arrange for the disposal of the unused medications Likvidaci nevyužitých léků zadavatel zajistí na vlastní náklady. At their own expense, during the clinical Trail and upon its completion, sponsor undertakes to, as the source of waste, hand over any unusable Sponsor´s Drug and Comparator Drug to an authorised person in accordance with Act No.185/2001 Coll. on Waste and its implementing regulations, as amended. Zadavatel se jako původce odpadu zavazuje, že zajistí na vlastní náklady, jak v průběhu, tak i po skončení klinického hodnocení, předání nepoužitelného léku zadavatele a srovnávacího léku oprávněné osobě v souladu s ustanoveními zákona č. 185/2001 Sb., o odpadech a jeho prováděcími předpisy v platném znění. Sponsor represents to meet any and all conditions stipulated by the relevant legislation concerning the manufacture (import) of the Investigational Products and their distribution to Zadavatel prohlašuje, že jsou splněny veškeré podmínky stanovené příslušnými právními předpisy pro výrobu (dovoz) léku zadavatele a jeho distribuci do zdravotnického zařízení. the Institution. The Parties acknowledge and confirm that the Trial, which is subject to this Agreement, is entirely independent from any persuasion to purchase medicinal products (medical devices) from CRO or the Sponsor, or from any decisions to purchase medicinal products (medical devices’) from CRO or the Sponsor, and shall have no impact on any ongoing or future agreements that may exist between ICON, the Sponsor, and the Institution. Smluvní strany shodně prohlašují, že klinické hodnocení dle této smlouvy nijak nesouvisí s odběrem léčivých přípravků (zdravotnických prostředků) od CRO nebo zadavatele, jakož i případným rozhodováním o pořízení léčivých prostředků (zdravotnických prostředků) od CRO nebo zadavatele, ani neovlivní existující nebo budoucí smluvní vztahy mezi...

Related to Ownership of Sponsor Drug and Comparator Drug

  • Function of Joint Health and Safety Committee All incidents involving aggression or violence shall be brought to the attention of the Joint Health and Safety Committee. The Employer agrees that the Joint Health and Safety Committee shall concern itself with all matters relating to violence to staff.

  • CERTIFICATION REGARDING DRUG-FREE WORKPLACE REQUIREMENTS The undersigned (authorized official signing for the contracting organization) certifies that the contractor will, or will continue to, provide a drug-free workplace in accordance with 45 CFR Part 76 by:

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Information Technology Enterprise Architecture Requirements If this Contract involves information technology-related products or services, the Contractor agrees that all such products or services are compatible with any of the technology standards found at xxxxx://xxx.xx.xxx/iot/2394.htm that are applicable, including the assistive technology standard. The State may terminate this Contract for default if the terms of this paragraph are breached.

  • Prescription Drug Plan Effective January 1, 2022, retail and mail order prescription drug copays for bargaining unit employees shall be as follows: Type of Drug Prescriptions for 1-45 Days (1 copay) Prescriptions for 46-90 Days (2 copays) Generic drug $10 $20 Preferred brand name drug $25 $50 Non- referred brand name drug $40 $80 Effective January 1, 2022, for each plan year the Prescription Drug annual out-of-pocket copay maximum shall be $1,000 for individual coverage and $1,500 for employee and spouse, employee and child, or employee and family coverage.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Health and Safety Plan 5. Xxxxxx shall prepare and submit under separate cover from the Work Plan, a Health and Safety Plan consistent with Occupational Safety and Health Administration regulations. The Health and Safety Plan shall be submitted to the Department in the form of one electronic copy on compact disk (in .pdf format). Xxxxxx agrees that the Health and Safety Plan is submitted to the Department only for informational purposes. The Department expressly disclaims any liability that may result from implementation of the Health and Safety Plan by Xxxxxx. PUBLIC PARTICIPATION

  • DRUG/ALCOHOL TESTING 8.1 The parties agree that the maintenance of a drug/alcohol free work place is a goal of both the College and the Union. Employees are prohibited from possession, consumption and/or being under the influence of a controlled substance/alcohol while on the College’s premises or during time paid by the employer. Violations of this prohibition may result in a disciplinary action up to and including termination.

  • Switching and Tagging Rules Each Party shall provide the other Parties a copy of its switching and tagging rules that are applicable to the other Parties’ activities. Such switching and tagging rules shall be developed on a non-discriminatory basis. The Parties shall comply with applicable switching and tagging rules, as amended from time to time, in obtaining clearances for work or for switching operations on equipment.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

Time is Money Join Law Insider Premium to draft better contracts faster.